U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 8, 2021
Cannapharmarx, Inc.
(Exact name of small business issuer as specified in its charter)
Delaware | 333-251016 | 24-4635140 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer ID No.) |
3600
888-3rd Street SW
Calgary, Alberta, Canada T2P5C5
(Address of principal executive offices)
(949) 652-6838
(Issuer’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | CPMD | OTC Pink Sheets |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 | Entry into a Material Definitive Agreement |
On December 22, 2020, we entered into Purchase and Sale Agreement with Just in Time Capital, Inc. as amended by the amendment of Agreement of Purchase and Sale dated June 1, 2021 (collectively the “PSA”). The material the terms of the Amendment are included in that certain Press Release attached hereto and incorporated herein as if set forth as Exhibit 99.6. The Purchase and Sale Agreement and the Amendment to the Purchase and Sale Agreement is attached hereto and incorporated herein as if set forth in Exhibit 10.5.
Item 7.01 | Regulation FD Disclosure |
Attached is a copy of a press release being issued by the Company relating to the Purchase and Sale Agreement, a copy of which is attached as Exhibit 99.6 and is hereby incorporated.
Item 9.01. | Financial Statements and Exhibits. |
(c) Exhibits.
Number | Exhibit |
10.5 | Purchase and Sale Agreement and the Amendment to the Purchase and Sale Agreement with Just in Time Capital, Inc. |
99.6 | Press Release |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 8, 2021 | CANNAPHARMARX, INC. |
By: /s/Dominic Colvin | |
Chief Executive Officer |
3 |